A Comprehensive Study of the Relationship between the Production of β-Lactamase Enzymes and Iron/Siderophore Uptake Regulatory Genes in Clinical Isolates of Acinetobacter baumannii

Table 2

The biofilm-forming capacity of A. baumannii and percentages of their iron/siderophore mediate gene.

Biofilm	Antibiotic resistance profiles (NO) (%)																	Total
	IMI	ERT	PIP	GEN	CIP	AMK	FOX	AZT	OFL	CEP	TMP/SMX		PIP/TAZ	MDR	XDR	AmpC	MBL
Strong	9	11	11	11	11	11	11	9	11	11	11		11	11	11	11	11	11
	47.3	52.3	44.4	35.4	50	52.3	55.0	100	37.9	55.0	64.7		100	50	84.6	55.0	42.3	15.2
Moderate	9	10	7	20	10	10	9	0	16	9	6		6	10	2	9	13	23
	47.3	47.6	38.8	64.5	45.4	47.6	45		55.1	45.0	35.2		33.3	45.5	18.1	45.0	50.0	31.9
Weak	1	0	0	0	0	0	0	0	1	0	0		1	1	0	0	0	5
	5.2								3.4				5.5	4.5				6.9
Nonbiofilm	0	0	0	0	1	0	0	0	1	0	0		0	0	0	0	2	33
	19	21	18	31	22	21	20	9	29	20	17		18	22	13	20	26	72
Total	26.3	29.1	25.0	43.0	30.5	29.1	27.7	12.5	40.2	27.7	23.6		25.0	30.5	18.0	27.7	36.1
Iron/siderophore mediate gene
BasD	9	9	8	9	9	9	9	9	9	9	9	9		9	9	9	9	9
	47.3	42.8	50.0	3.2	41.0	42.8	45.0	100	31.0	45.0	52.9	81.1		40.9	69.2	45.0	34.6	12.5
BauA	11	11	11	11	11	11	11	9	11	11	11	11		11	11	9	9	11
	57.8	52.3	61.1	35.4	50.0	52.3	55.0	100	37.9	55.0	64.7	61.1		50.0	84.6	27.7	34.6	15.2
Pld	8	8	8	8	8	8	8	8	8	8	8	8		8	8	8	7	8
	42.1	38.0	44.4	25.8	36.6	38.0	40.0	88.9	27.5	40	47.0	44.4		36.3	61.5	40.0	26.9	11.1
paaE	7	11	11	11	9	11	11	9	11	11	11	11		10	9	11	11	11
	36.8	52.3	61.1	35.4	40.0	52.3	55.0	100	31.0	55.0	64.7	61.1		45.5	69.2	55.0	42.3	15.2
feoB	9	11	11	12	12	11	12	9	11	12	11	12		11	12	11	9	12
	47.3	52.3	52.3	38.7	57.1	52.3	60.0	100	37.9	60.0	64.7	66.6		50.0	92.3	55.0	34.6	16.6
entA	14	13	14	12	12	14	12	9	14	13	14	14		13	13	14	13	14
	73.6	61.9	77.7	38.7	38.7	52.3	66.6	100	48.2	65.0	82.3	77.7		59.0	100	70.0	50.0	19.4
hemO	17	15	17	17	17	16	14	9	17	17	17	17		17	12	14	11	17
	89.4	71.4	100	54.8	77.2	76.1	70.0	100	58.6	85.0	100	94.4		77.2	92.3	70.0	42.3	23.6
tonB	5	5	5	4	5	5	3	5	5	0	0	4		5	5	5	4	5
	26.3	23.8	27.7	12.9	22.7	23.8	15	55.5	17.2			22.2		22.7	38.4	25.0	15.3	6.9
Clinical samples
Wound	19	20	10	9	2	11	9	7	16	10	10	9		13	7	9	13	23
	100	95.2	55.5	29.0	9.0	52.3	45.0	77.7	55.1	50.0	58.8	50.0		59.0	53.8	45.0	50.0	31.9
Urine	0	0	2	20	18	1	2	0	3	2	3	2		2	2	2	4	21
			11.1	64.5	81.8	4.7	10		10.3	10.0	17.6	11.1		9.0	15.38	10.0	15.3	29.1
Blood	0	0	5	1	2	9	9	2	7	7	3	6		7	4	9	7	18
			27.7	3.2	9.0	42.8	45.0	28.5	24.1	35.0	17.6	33.3		31.8	30.7	45.0	26.9	25.0
Body fluids	0	1	1	1	0	0	0	0	3	1	1	1		0	0	0	2	10
		4.7	5.5	3.2					10.3	5	5.8	5.5					7.6	13.8

IMI: imipenem; ERT: ertapenem; PIP: piperacillin; GEN: gentamycin; CIP: ciprofloxacin; AMK: amikacin; FOX: cefoxitin; AZT: aztreonam; OFL: ofloxacin; PIP/TAZ: piperacillin/tazobactam; TMP/SMX: trimethoprim/sulfamethoxazole; CEP: cefepime; MDR: multidrug-resistant; XDR: extensively drug-resistant; AmpC: ampicillins C; MBL: metallo-β-lactamase.